. 2021 Nov 13;11(1):123–135. doi: 10.1007/s40120-021-00295-8

Table 2.

Rank order probabilities of the first rank: likelihood of being the best treatment option for time-to-first relapse in adults with AQP4+ NMOSD

Treatment	Analysis 1: combined mono- and combination therapy	Analysis 2: monotherapy	Analysis 3: combination therapy
Eculizumab	97.63%	98.67%	84.47%
Inebilizumab^a	–	00.74%	–
Satralizumab	02.37%	00.59%	15.53%
Placebo	0	0	0

AQP4+ aquaporin-4 immunoglobulin G-positive, NMOSD neuromyelitis optica spectrum disorder

^aInebilizumab only has monotherapy data and was not included in Analysis 1 or 3